CollabRx Forms Pan Cancer Molecular Oncology Editorial Board
Razelle Kurzrock, M.D., Named as Chief Editor
SAN FRANCISCO, March 26, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc.
(Nasdaq:CLRX), a data analytics company focused on informing clinical decision
making in molecular medicine, today announced the formation of a Pan Cancer
(biomarker-focused) molecular oncology editorial board to be led by Razelle
Kurzrock, M.D., who will serve as Chief Editor.
Dr. Kurzrock is Director of the Center for Personalized Therapy at UC San
Diego Moores Cancer Center, Vice Chief of the Hematology-Oncology Division in
the UC San Diego School of Medicine and Senior Deputy Center Director,
Clinical Science, for UC San Diego Moores Cancer Center. Previously, Dr.
Kurzrock developed one of the largest Phase 1 clinical trials programs in the
nation at the MD Anderson Cancer Center. A central theme of that program was a
personalized medicine strategy that utilized advanced molecular technologies
to match patients with targeted cancer treatments that optimized chances for
Dr. Kurzrock leads a distinguished group of physicians from UC San Diego, MD
Anderson Cancer Center, and other institutions both in the US and abroad.
Background about the complete editorial board can be found on the company's
The newly formed Pan Cancer board is the most recent addition among CollabRx's
existing editorial boards, which identify clinically actionable biomarkers in
the context of individual cancer types such as lung cancer or melanoma. The
Pan Cancer editorial board is differentiated in that it will apply a broad
molecular oncology perspective in the identification of biomarkers that are
clinically actionable in any cancer type. Both types of editorial boards link
biomarkers to therapy considerations including drugs and clinical trials. This
complementary approach supports the emerging view in personalized oncology
that cancers are defined not just by their tissue of origin (e.g., lung
cancer), but also by the molecular aberrations they harbor (e.g., EGFR
mutations) that can be targeted by specific drugs or combinations of drugs
(e.g., EGFR inhibitors).
"It is with great pleasure and anticipation that I assume my new role as Chief
Editor of the Pan Cancer editorial board," said Dr. Kurzrock. "I look forward
to working with my board and CollabRx staff to provide our physician
colleagues with a high-level understanding of how tumor genetics are being
leveraged in therapy development and to develop a best-in-class online
educational resource for understanding how to use tumor genetic profiles to
inform treatment planning for cancer patients."
The Pan Cancer board's initial activities will focus on the development of a
Web-based application that will associate specific biomarkers with
expert-vetted and clinically relevant information on drugs and clinical
trials. The application functionality will be extended in stages and at launch
will address sequencing-based biomarkers such as gene mutations,
insertions/deletions, fusions and other aberrations. CollabRx will make a
version of this application freely available online for physicians and
researchers to learn about clinically actionable biomarkers in any cancer
type. Subsequently, pathologists and oncologists will be able to use the
application at the point of care to annotate their own data generated on any
next-generation sequencing platform or sequencing-based test results obtained
from any laboratory.
"The formation of a Pan Cancer editorial board illustrates our company's
strategy of developing products and services for pathologists and
laboratories, and it represents a significant step forward in our commitment
to provide a best-in-class, expert-vetted interpretation to next-generation
clinical cancer sequencing panels," said Thomas Mika, Chairman, President &
Chief Executive Officer of CollabRx. "We are honored that Dr. Kurzrock and her
board members are joining our large and growing expert advisory network and
are working with us to assist physicians in matching patients to targeted
agents based on actionable genetic aberrations."
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform health care decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at http://www.collabrx.com.
The CollabRx, Inc. logo is available at
CONTACT: Thomas R. Mika, CEO
Robert Ferri Partners, LLC
(415) 575-1589 (direct)
CollabRx, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.